ATE435906T1 - Verfahren zur reinigung von viren - Google Patents

Verfahren zur reinigung von viren

Info

Publication number
ATE435906T1
ATE435906T1 AT06126383T AT06126383T ATE435906T1 AT E435906 T1 ATE435906 T1 AT E435906T1 AT 06126383 T AT06126383 T AT 06126383T AT 06126383 T AT06126383 T AT 06126383T AT E435906 T1 ATE435906 T1 AT E435906T1
Authority
AT
Austria
Prior art keywords
cleaning viruses
adenovirus
viruses
cleaning
preparation
Prior art date
Application number
AT06126383T
Other languages
English (en)
Inventor
Miranda Weggeman
Corven Emile Joannes Josephus Maria Van
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34878416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE435906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE435906T1 publication Critical patent/ATE435906T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06126383T 2004-02-23 2005-02-21 Verfahren zur reinigung von viren ATE435906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2004050190 2004-02-23

Publications (1)

Publication Number Publication Date
ATE435906T1 true ATE435906T1 (de) 2009-07-15

Family

ID=34878416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06126383T ATE435906T1 (de) 2004-02-23 2005-02-21 Verfahren zur reinigung von viren

Country Status (13)

Country Link
US (2) US20070207461A1 (de)
EP (2) EP1780269B1 (de)
JP (1) JP2007522814A (de)
KR (1) KR101211329B1 (de)
CN (2) CN101343625A (de)
AT (1) ATE435906T1 (de)
AU (1) AU2005214090B2 (de)
CA (1) CA2555412C (de)
DE (1) DE602005015332D1 (de)
DK (1) DK1780269T3 (de)
ES (1) ES2329607T3 (de)
NZ (1) NZ548495A (de)
WO (1) WO2005080556A2 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
EP1998804B1 (de) * 2006-03-27 2014-04-16 Crucell Holland B.V. Zusammensetzungen, die einen rekombinanten adenovirus und ein adjuvans umfassen
US7875446B2 (en) * 2006-04-20 2011-01-25 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
EP2195418B1 (de) 2007-10-02 2012-12-12 PTC Phage Technology Center GmbH Verfahren und system zur grosstechnischen aufreinigung von für eine bakteriophagentherapie vorgesehenen bakteriophagen
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
DK2307551T3 (en) * 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
US8785173B2 (en) 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
US20110293660A1 (en) * 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
JP2010207800A (ja) * 2009-02-16 2010-09-24 Kuraray Co Ltd ろ過ユニットおよびこれを備えたろ過装置
JP2010193720A (ja) * 2009-02-23 2010-09-09 Asahi Kasei Chemicals Corp アニオン交換基が固定された多孔膜を用いたウイルスの分離方法
US8609392B2 (en) * 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
ES2565335T3 (es) * 2009-08-17 2016-04-04 Merck Patent Gmbh Método para aislar virus
JP5393896B2 (ja) 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー アデノウイルス粒子の精製方法
CA2777116C (en) 2009-10-15 2020-09-01 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
JP5945270B2 (ja) * 2010-07-20 2016-07-05 バヴァリアン・ノルディック・アクティーゼルスカブ 発現産物を採取するための方法
WO2012019354A1 (en) 2010-08-12 2012-02-16 Yisheng Biopharma Holdings Ltd. Method for reducing dna impurities in viral compositions
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
US9273289B2 (en) * 2010-11-26 2016-03-01 Probiogen Ag Depletion of host cell components from live vector vaccines
KR20140038517A (ko) * 2011-06-13 2014-03-28 머크 샤프 앤드 돔 코포레이션 천연 또는 돌연변이 형태의 디프테리아 독소의 정제 방법
ES2726975T3 (es) * 2011-07-27 2019-10-11 Flash Therapeutics Método para la producción de partículas retrovíricas útiles para transducir células eucariotas
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN103571800B (zh) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 一种去除疫苗中宿主dna的方法
RU2493872C1 (ru) * 2012-08-08 2013-09-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации ( ФГУП "НПО "Микроген" Минздрава России) Способ очистки вируса гриппа
CN103768589B (zh) * 2012-10-18 2016-12-21 辽宁成大生物股份有限公司 利用中空纤维膜去除人用乙型脑炎疫苗制品中残留dna的方法
BR112015021297A2 (pt) * 2013-02-28 2017-10-10 Psioxus Therapeutics Ltd um processo para a produção de adenovírus.
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CA2914790C (en) 2013-06-14 2024-02-27 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3172317B1 (de) * 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Verfahren zur reinigung von poliovirus aus zellkulturen
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
US10954492B2 (en) 2015-06-10 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
CN106434571A (zh) * 2016-10-19 2017-02-22 深圳源兴基因技术有限公司 一种wave无血清培养悬浮细胞制备重组腺病毒的方法
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
CN106868025B (zh) * 2017-03-13 2020-01-21 中国人民解放军军事医学科学院生物工程研究所 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
GB201814590D0 (en) * 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
WO2019209632A1 (en) 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
IL279295B2 (en) 2018-06-12 2026-03-01 Kentucky Bioprocessing Inc Purification and cross-linking of virus and antigen
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CA3120129A1 (en) * 2018-11-21 2020-05-28 Western Oncolytics Ltd. Manufacture of virus
MX2021013950A (es) * 2019-05-14 2022-01-04 Janssen Biotech Inc Eliminacion eficaz de impurezas usando un proceso de diafiltracion.
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
CN114173827B (zh) * 2019-06-28 2025-01-28 武田药品工业株式会社 腺相关病毒纯化方法
IL295154A (en) * 2020-01-28 2022-09-01 Lonza Walkersville Inc Methods for determining viral titer
CN111249456A (zh) * 2020-03-13 2020-06-09 武汉生物制品研究所有限责任公司 一种狂犬病病毒灭活疫苗的纯化方法
CN111394390A (zh) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法
US20230302381A1 (en) * 2020-08-18 2023-09-28 Sartorius Bia Separations D.O.O. Metal-affinity extraction of host cell dna
US12577540B2 (en) 2020-12-10 2026-03-17 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells
AU2022279062A1 (en) 2021-05-17 2024-01-04 Sarepta Therapeutics, Inc. Production of recombinant aav vectors for treating muscular dystrophy
KR20240042648A (ko) * 2021-08-10 2024-04-02 바이오콘 리미티드 리라글루티드의 정제
CN113817689B (zh) * 2021-11-22 2023-10-03 北京艺妙神州医药科技有限公司 慢病毒纯化工艺
JP2025510977A (ja) * 2022-03-30 2025-04-15 シーエスエル・ベーリング・エルエルシー エンベロープ型ウイルスを精製する方法
CN115807064A (zh) * 2022-07-20 2023-03-17 上海泰昶生物技术有限公司 重组腺相关病毒载体制品中游离和错误包装dna的检测方法
CN115141813A (zh) * 2022-07-29 2022-10-04 深圳源兴基因技术有限公司 一种高效去除宿主细胞残留蛋白的腺病毒纯化方法
EP4590838A1 (de) 2022-09-23 2025-07-30 Sarepta Therapeutics, Inc. Rekombinante aav-vektoren zur behandlung von muskeldystrophie
EP4634371A1 (de) * 2022-12-16 2025-10-22 Avirmax Biopharma Inc. Verfahren zur herstellung von viren und viruspartikeln

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434914B (sv) * 1975-07-07 1984-08-27 Jonsson U R S Forfarande for att ur en suspension av bakterier och ett vetskeformigt medium genom filtrering avskilja mediet under samtidig anrikning av bakterierna
US4435289A (en) * 1981-12-23 1984-03-06 Romicon, Inc. Series ultrafiltration with pressurized permeate
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US4808315A (en) * 1986-04-28 1989-02-28 Asahi Kasei Kogyo Kabushiki Kaisha Porous hollow fiber membrane and a method for the removal of a virus by using the same
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) * 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) * 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6168944B1 (en) * 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
EP0981601B1 (de) 1997-01-31 2006-09-06 Schering Corporation Verfahren zur kultivierung von zellen und zur vermehrung von viren
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5947689A (en) * 1997-05-07 1999-09-07 Scilog, Inc. Automated, quantitative, system for filtration of liquids having a pump controller
DK1025209T3 (da) * 1997-08-28 2007-06-25 Cheil Jedang Corp Et attenueret japansk encephalitis-virus tilpasset til Vero-celle og en japansk encephalitis-vaccine
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
IL137510A0 (en) 1998-02-17 2001-07-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
IL139040A0 (en) * 1998-04-22 2001-11-25 Genvec Inc Efficient purification of adenovirus
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6342384B1 (en) * 1998-08-21 2002-01-29 The University Of Va Patent Foundation Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
NZ512504A (en) * 1998-12-31 2004-01-30 Aventis Pharma Sa Method for separating viral particles
JP4802366B2 (ja) 1999-02-22 2011-10-26 トランスジェン・ソシエテ・アノニム 精製ウイルス調製物の取得方法
US6120820A (en) * 1999-02-22 2000-09-19 Land O'lakes, Inc. Method of modifying the color of a dairy material
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
DE10022258A1 (de) * 2000-05-08 2001-11-15 Bayer Ag Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
US6365395B1 (en) * 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
ATE496120T1 (de) 2001-03-01 2011-02-15 Bayer Schering Pharma Ag Konzentration und lyse von adenovirus-infizierten zellen in derselben prozesseinheit
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
EP1492890A4 (de) 2002-03-29 2006-10-18 Merck & Co Inc Verfahren im grossmassstab zur produktion von adenovirus und adenovirus-stammlösungen zur aussaat
EP1497440B1 (de) 2002-04-25 2008-08-20 Crucell Holland B.V. Stabile adenovirale vektoren und methoden für deren vermehrung
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
US20050095705A1 (en) 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
EP1633321A4 (de) * 2003-06-18 2006-11-02 Onyx Pharma Inc Verfahren zur reinigung von virus
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
US20060078628A1 (en) * 2004-10-09 2006-04-13 Karl Koman Wound treating agent

Also Published As

Publication number Publication date
WO2005080556A9 (en) 2006-10-26
DK1780269T3 (da) 2009-10-12
WO2005080556A3 (en) 2006-02-23
CA2555412C (en) 2013-06-25
DE602005015332D1 (de) 2009-08-20
JP2007522814A (ja) 2007-08-16
AU2005214090B2 (en) 2008-09-11
WO2005080556A2 (en) 2005-09-01
KR101211329B1 (ko) 2012-12-12
EP1780269A2 (de) 2007-05-02
ES2329607T3 (es) 2009-11-27
EP1780269A3 (de) 2007-07-18
CN101343625A (zh) 2009-01-14
EP1718738A2 (de) 2006-11-08
CN1922308A (zh) 2007-02-28
US20070207461A1 (en) 2007-09-06
AU2005214090A1 (en) 2005-09-01
US20090017523A1 (en) 2009-01-15
EP1780269B1 (de) 2009-07-08
US8124106B2 (en) 2012-02-28
NZ548495A (en) 2009-05-31
CA2555412A1 (en) 2005-09-01
KR20070001163A (ko) 2007-01-03

Similar Documents

Publication Publication Date Title
ATE435906T1 (de) Verfahren zur reinigung von viren
ATE446792T1 (de) Verfahren zur behandlung von sinuskopfschmerzen
EP1726599A4 (de) Verfahren zur herstellung von fluorpolymer
ATE431139T1 (de) Verfahren zur identifizierung von glp-1- sekretionsförderern
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
DE502004009763D1 (de) Verfahren zur herstellung von 1-buten
DE602004010234D1 (de) Verfahren zur herstellung von 4-aminodiphenylamin
DE502004009768D1 (de) Verfahren zur herstellung von dreiwertigen organophosphor-verbindungen
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
DE60234952D1 (de) VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE60217096D1 (de) Verfahren zur herstellung von (s)-(+)- und (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepin-5-carboxamid
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE502005010038D1 (de) Verfahren zur herstellung von 3-pentennitril
DE60302139D1 (de) Verfahren zur herstellung von aripiprazole
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
ATE514673T1 (de) Verfahren zur trennung von pentennitril-isomeren
DE502004001216D1 (de) Verfahren zur aufreinigung von blausäure
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
DE502006002510D1 (de) Verfahren zur herstellung von silikon-haltigen polymerisaten
DE60226310D1 (de) Verfahren zur herstellung von cycloolefinadditionspolymerisat
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
DE60233130D1 (de) Verfahren zur herstellung von imipenem
DE502004002810D1 (de) Verfahren zur herstellung von copolymerisaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1780269

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1780269

Country of ref document: EP